LobbyingInjective lobbying by quarter
Injective's latest lobbying report covers Q2 2026, at $70K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q4 2025; the issues it reports most are Financial Institutions/Investments/Securities and Taxation/Internal Revenue Code.
Injective
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $180K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $40K | 1 |
| Q1 2026 | $70K | 1 |
| Q2 2026 | $70K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Financial institutions and securities$46.7K · 2 reports
- Taxation$46.7K · 2 reports
- Banking$43.3K · 2 reports
- Commodities$23.3K · 1 reports
- Agriculture$20K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Commerce, Dept of (DOC)1 reports
- Federal Reserve System1 reports
- Securities & Exchange Commission (SEC)1 reports
- Treasury, Dept of1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseInjective | $180K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $70K |
| 04/20for Q1 | In-house | $70K |
| 01/20for Q4 2025 | In-house | $40K |
| 25/11/14for Q4 2025 | In-house | Under $5,000 |